Oral drug dosing following bariatric surgery: General concepts and specific dosing advice
Bariatric or weight‐loss surgery is a popular option for weight reduction. Depending on the surgical procedure, gastric changes like decreased transit time and volume and increased pH, decreased absorption surface in the small intestine, decreased exposure to bile acids and enterohepatic circulation...
Gespeichert in:
Veröffentlicht in: | British journal of clinical pharmacology 2021-12, Vol.87 (12), p.4560-4576 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 4576 |
---|---|
container_issue | 12 |
container_start_page | 4560 |
container_title | British journal of clinical pharmacology |
container_volume | 87 |
creator | Kingma, Jurjen S. Burgers, Desirée M. T. Monpellier, Valerie M. Wiezer, Marinus J. Blussé van Oud‐Alblas, Heleen J. Vaughns, Janelle D. Sherwin, Catherine M. T. Knibbe, Catherijne A. J. |
description | Bariatric or weight‐loss surgery is a popular option for weight reduction. Depending on the surgical procedure, gastric changes like decreased transit time and volume and increased pH, decreased absorption surface in the small intestine, decreased exposure to bile acids and enterohepatic circulation, and decreased gastrointestinal transit time may be expected. In the years after bariatric surgery, patients will also substantially lose weight. As a result of these changes, the absorption, distribution, metabolism and/or elimination of drugs may be altered. The purpose of this article is to report the general influence of bariatric surgery on oral drug absorption, and to provide guidance for dosing of commonly used drugs in this special population. Upon oral drug administration, the time to maximum concentration is often earlier and this concentration may be higher with less consistent effects on trough concentrations and exposure. Additionally, prescription of liquid formulations to bariatric patients is supported by some reports, even though the high sugar load of these suspensions may be of concern. Studies on extended‐release medications result in an unaltered exposure for a substantial number of drugs. Also, studies evaluating the influence of timing after surgery show dynamic absorption profiles. Although for this group specific advice can be proposed for many drugs, we conclude that there is insufficient evidence for general advice for oral drug therapy after bariatric surgery, implying that a risk assessment on a case‐by‐case basis is required for each drug. |
doi_str_mv | 10.1111/bcp.14913 |
format | Article |
fullrecord | <record><control><sourceid>wiley_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9291886</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>BCP14913</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4153-4c4d69d03fb065b99701f937f299f25c772f5b3a4fd188fb5369fbb41e3912783</originalsourceid><addsrcrecordid>eNp1kDtPwzAYRS0EoqUw8AdQVoa0fsRJzYAEFRSkSmWAgcnyMxilSWT3of57XFIqGPBiSz73fJ8uAJcIDlE8I6naIcoYIkegj0hOU4wwPQZ9SGCeUkxRD5yF8AkhIiinp6BHCGOQjVEfvM-9qBLtV2Wim-DqMrFNVTWb3UsK78TSO5WElS-N394kU1ObXUA1tTLtMiSi1klojXI2YnuD0GunzDk4saIK5mJ_D8Db48Pr5CmdzafPk7tZqjJESZqpTOdMQ2IlzKlkrIDIMlJYzJjFVBUFtlQSkVmNxmMrKcmZlTJDhjCEizEZgNvO267kwmhl6mXckLfeLYTf8kY4_vendh-8bNacYRaNeRRcdwLlmxC8sYcsgnzXL4_98u9-I3v1e9iB_Ck0AqMO2LjKbP838fvJS6f8AhSshmU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Oral drug dosing following bariatric surgery: General concepts and specific dosing advice</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Online Library Free Content</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Kingma, Jurjen S. ; Burgers, Desirée M. T. ; Monpellier, Valerie M. ; Wiezer, Marinus J. ; Blussé van Oud‐Alblas, Heleen J. ; Vaughns, Janelle D. ; Sherwin, Catherine M. T. ; Knibbe, Catherijne A. J.</creator><creatorcontrib>Kingma, Jurjen S. ; Burgers, Desirée M. T. ; Monpellier, Valerie M. ; Wiezer, Marinus J. ; Blussé van Oud‐Alblas, Heleen J. ; Vaughns, Janelle D. ; Sherwin, Catherine M. T. ; Knibbe, Catherijne A. J.</creatorcontrib><description>Bariatric or weight‐loss surgery is a popular option for weight reduction. Depending on the surgical procedure, gastric changes like decreased transit time and volume and increased pH, decreased absorption surface in the small intestine, decreased exposure to bile acids and enterohepatic circulation, and decreased gastrointestinal transit time may be expected. In the years after bariatric surgery, patients will also substantially lose weight. As a result of these changes, the absorption, distribution, metabolism and/or elimination of drugs may be altered. The purpose of this article is to report the general influence of bariatric surgery on oral drug absorption, and to provide guidance for dosing of commonly used drugs in this special population. Upon oral drug administration, the time to maximum concentration is often earlier and this concentration may be higher with less consistent effects on trough concentrations and exposure. Additionally, prescription of liquid formulations to bariatric patients is supported by some reports, even though the high sugar load of these suspensions may be of concern. Studies on extended‐release medications result in an unaltered exposure for a substantial number of drugs. Also, studies evaluating the influence of timing after surgery show dynamic absorption profiles. Although for this group specific advice can be proposed for many drugs, we conclude that there is insufficient evidence for general advice for oral drug therapy after bariatric surgery, implying that a risk assessment on a case‐by‐case basis is required for each drug.</description><identifier>ISSN: 0306-5251</identifier><identifier>EISSN: 1365-2125</identifier><identifier>DOI: 10.1111/bcp.14913</identifier><identifier>PMID: 33990981</identifier><language>eng</language><publisher>England: John Wiley and Sons Inc</publisher><subject>Administration, Oral ; Bariatric Surgery - adverse effects ; Bariatric Surgery - methods ; clinical pharmacology ; Drug-Related Side Effects and Adverse Reactions ; Enterohepatic Circulation ; Humans ; Invited Review ; nutrition ; obesity ; Pharmaceutical Preparations - administration & dosage ; pharmacokinetics ; Pharmacology ; surgery ; Weight Loss</subject><ispartof>British journal of clinical pharmacology, 2021-12, Vol.87 (12), p.4560-4576</ispartof><rights>2021 The Authors. published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.</rights><rights>2021 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4153-4c4d69d03fb065b99701f937f299f25c772f5b3a4fd188fb5369fbb41e3912783</citedby><cites>FETCH-LOGICAL-c4153-4c4d69d03fb065b99701f937f299f25c772f5b3a4fd188fb5369fbb41e3912783</cites><orcidid>0000-0002-0844-3207 ; 0000-0001-9893-4415</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbcp.14913$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbcp.14913$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33990981$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kingma, Jurjen S.</creatorcontrib><creatorcontrib>Burgers, Desirée M. T.</creatorcontrib><creatorcontrib>Monpellier, Valerie M.</creatorcontrib><creatorcontrib>Wiezer, Marinus J.</creatorcontrib><creatorcontrib>Blussé van Oud‐Alblas, Heleen J.</creatorcontrib><creatorcontrib>Vaughns, Janelle D.</creatorcontrib><creatorcontrib>Sherwin, Catherine M. T.</creatorcontrib><creatorcontrib>Knibbe, Catherijne A. J.</creatorcontrib><title>Oral drug dosing following bariatric surgery: General concepts and specific dosing advice</title><title>British journal of clinical pharmacology</title><addtitle>Br J Clin Pharmacol</addtitle><description>Bariatric or weight‐loss surgery is a popular option for weight reduction. Depending on the surgical procedure, gastric changes like decreased transit time and volume and increased pH, decreased absorption surface in the small intestine, decreased exposure to bile acids and enterohepatic circulation, and decreased gastrointestinal transit time may be expected. In the years after bariatric surgery, patients will also substantially lose weight. As a result of these changes, the absorption, distribution, metabolism and/or elimination of drugs may be altered. The purpose of this article is to report the general influence of bariatric surgery on oral drug absorption, and to provide guidance for dosing of commonly used drugs in this special population. Upon oral drug administration, the time to maximum concentration is often earlier and this concentration may be higher with less consistent effects on trough concentrations and exposure. Additionally, prescription of liquid formulations to bariatric patients is supported by some reports, even though the high sugar load of these suspensions may be of concern. Studies on extended‐release medications result in an unaltered exposure for a substantial number of drugs. Also, studies evaluating the influence of timing after surgery show dynamic absorption profiles. Although for this group specific advice can be proposed for many drugs, we conclude that there is insufficient evidence for general advice for oral drug therapy after bariatric surgery, implying that a risk assessment on a case‐by‐case basis is required for each drug.</description><subject>Administration, Oral</subject><subject>Bariatric Surgery - adverse effects</subject><subject>Bariatric Surgery - methods</subject><subject>clinical pharmacology</subject><subject>Drug-Related Side Effects and Adverse Reactions</subject><subject>Enterohepatic Circulation</subject><subject>Humans</subject><subject>Invited Review</subject><subject>nutrition</subject><subject>obesity</subject><subject>Pharmaceutical Preparations - administration & dosage</subject><subject>pharmacokinetics</subject><subject>Pharmacology</subject><subject>surgery</subject><subject>Weight Loss</subject><issn>0306-5251</issn><issn>1365-2125</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp1kDtPwzAYRS0EoqUw8AdQVoa0fsRJzYAEFRSkSmWAgcnyMxilSWT3of57XFIqGPBiSz73fJ8uAJcIDlE8I6naIcoYIkegj0hOU4wwPQZ9SGCeUkxRD5yF8AkhIiinp6BHCGOQjVEfvM-9qBLtV2Wim-DqMrFNVTWb3UsK78TSO5WElS-N394kU1ObXUA1tTLtMiSi1klojXI2YnuD0GunzDk4saIK5mJ_D8Db48Pr5CmdzafPk7tZqjJESZqpTOdMQ2IlzKlkrIDIMlJYzJjFVBUFtlQSkVmNxmMrKcmZlTJDhjCEizEZgNvO267kwmhl6mXckLfeLYTf8kY4_vendh-8bNacYRaNeRRcdwLlmxC8sYcsgnzXL4_98u9-I3v1e9iB_Ck0AqMO2LjKbP838fvJS6f8AhSshmU</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>Kingma, Jurjen S.</creator><creator>Burgers, Desirée M. T.</creator><creator>Monpellier, Valerie M.</creator><creator>Wiezer, Marinus J.</creator><creator>Blussé van Oud‐Alblas, Heleen J.</creator><creator>Vaughns, Janelle D.</creator><creator>Sherwin, Catherine M. T.</creator><creator>Knibbe, Catherijne A. J.</creator><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0844-3207</orcidid><orcidid>https://orcid.org/0000-0001-9893-4415</orcidid></search><sort><creationdate>202112</creationdate><title>Oral drug dosing following bariatric surgery: General concepts and specific dosing advice</title><author>Kingma, Jurjen S. ; Burgers, Desirée M. T. ; Monpellier, Valerie M. ; Wiezer, Marinus J. ; Blussé van Oud‐Alblas, Heleen J. ; Vaughns, Janelle D. ; Sherwin, Catherine M. T. ; Knibbe, Catherijne A. J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4153-4c4d69d03fb065b99701f937f299f25c772f5b3a4fd188fb5369fbb41e3912783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Administration, Oral</topic><topic>Bariatric Surgery - adverse effects</topic><topic>Bariatric Surgery - methods</topic><topic>clinical pharmacology</topic><topic>Drug-Related Side Effects and Adverse Reactions</topic><topic>Enterohepatic Circulation</topic><topic>Humans</topic><topic>Invited Review</topic><topic>nutrition</topic><topic>obesity</topic><topic>Pharmaceutical Preparations - administration & dosage</topic><topic>pharmacokinetics</topic><topic>Pharmacology</topic><topic>surgery</topic><topic>Weight Loss</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kingma, Jurjen S.</creatorcontrib><creatorcontrib>Burgers, Desirée M. T.</creatorcontrib><creatorcontrib>Monpellier, Valerie M.</creatorcontrib><creatorcontrib>Wiezer, Marinus J.</creatorcontrib><creatorcontrib>Blussé van Oud‐Alblas, Heleen J.</creatorcontrib><creatorcontrib>Vaughns, Janelle D.</creatorcontrib><creatorcontrib>Sherwin, Catherine M. T.</creatorcontrib><creatorcontrib>Knibbe, Catherijne A. J.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kingma, Jurjen S.</au><au>Burgers, Desirée M. T.</au><au>Monpellier, Valerie M.</au><au>Wiezer, Marinus J.</au><au>Blussé van Oud‐Alblas, Heleen J.</au><au>Vaughns, Janelle D.</au><au>Sherwin, Catherine M. T.</au><au>Knibbe, Catherijne A. J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oral drug dosing following bariatric surgery: General concepts and specific dosing advice</atitle><jtitle>British journal of clinical pharmacology</jtitle><addtitle>Br J Clin Pharmacol</addtitle><date>2021-12</date><risdate>2021</risdate><volume>87</volume><issue>12</issue><spage>4560</spage><epage>4576</epage><pages>4560-4576</pages><issn>0306-5251</issn><eissn>1365-2125</eissn><abstract>Bariatric or weight‐loss surgery is a popular option for weight reduction. Depending on the surgical procedure, gastric changes like decreased transit time and volume and increased pH, decreased absorption surface in the small intestine, decreased exposure to bile acids and enterohepatic circulation, and decreased gastrointestinal transit time may be expected. In the years after bariatric surgery, patients will also substantially lose weight. As a result of these changes, the absorption, distribution, metabolism and/or elimination of drugs may be altered. The purpose of this article is to report the general influence of bariatric surgery on oral drug absorption, and to provide guidance for dosing of commonly used drugs in this special population. Upon oral drug administration, the time to maximum concentration is often earlier and this concentration may be higher with less consistent effects on trough concentrations and exposure. Additionally, prescription of liquid formulations to bariatric patients is supported by some reports, even though the high sugar load of these suspensions may be of concern. Studies on extended‐release medications result in an unaltered exposure for a substantial number of drugs. Also, studies evaluating the influence of timing after surgery show dynamic absorption profiles. Although for this group specific advice can be proposed for many drugs, we conclude that there is insufficient evidence for general advice for oral drug therapy after bariatric surgery, implying that a risk assessment on a case‐by‐case basis is required for each drug.</abstract><cop>England</cop><pub>John Wiley and Sons Inc</pub><pmid>33990981</pmid><doi>10.1111/bcp.14913</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0002-0844-3207</orcidid><orcidid>https://orcid.org/0000-0001-9893-4415</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0306-5251 |
ispartof | British journal of clinical pharmacology, 2021-12, Vol.87 (12), p.4560-4576 |
issn | 0306-5251 1365-2125 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9291886 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Wiley Online Library Free Content; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
subjects | Administration, Oral Bariatric Surgery - adverse effects Bariatric Surgery - methods clinical pharmacology Drug-Related Side Effects and Adverse Reactions Enterohepatic Circulation Humans Invited Review nutrition obesity Pharmaceutical Preparations - administration & dosage pharmacokinetics Pharmacology surgery Weight Loss |
title | Oral drug dosing following bariatric surgery: General concepts and specific dosing advice |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T21%3A13%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oral%20drug%20dosing%20following%20bariatric%20surgery:%20General%20concepts%20and%20specific%20dosing%20advice&rft.jtitle=British%20journal%20of%20clinical%20pharmacology&rft.au=Kingma,%20Jurjen%20S.&rft.date=2021-12&rft.volume=87&rft.issue=12&rft.spage=4560&rft.epage=4576&rft.pages=4560-4576&rft.issn=0306-5251&rft.eissn=1365-2125&rft_id=info:doi/10.1111/bcp.14913&rft_dat=%3Cwiley_pubme%3EBCP14913%3C/wiley_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/33990981&rfr_iscdi=true |